Investment Thesis
Alto Neuroscience is a well-capitalized pre-revenue biotech with exceptional financial runway (263.8M cash, 0.06x leverage) and improving loss trajectory, but fundamentals lack the revenue generation and profitability path needed for buy conviction. Success depends entirely on pipeline execution and clinical milestone achievement.
Strengths
- Exceptional cash position ($263.8M) with 9+ year runway at current burn rate
- Fortress balance sheet with minimal debt ($13.9M) and 0.06x D/E ratio
- Improving loss trajectory with net income losses declining 2.9% YoY and diluted EPS improving 12.4% YoY
Risks
- Pre-revenue status with no commercialized products generating material revenue
- Significant cash burn rate of $27.1M operating cash outflow annually
- Negative returns on equity (-10.8%) and assets (-9.5%) with no visible path to profitability
Key Metrics to Watch
- Operating cash burn rate trends and remaining runway
- Clinical development milestone progression and pipeline advancement
- Quarterly revenue initiation and commercial product launch timeline
Financial Metrics
Revenue
N/A
Net Income
-26.2M
EPS (Diluted)
$-0.80
Free Cash Flow
-27.6M
Total Assets
276.3M
Cash
263.8M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-10.8%
ROA
-9.5%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
20.52x
Quick Ratio
20.52x
Debt/Equity
0.06x
Debt/Assets
11.9%
Interest Coverage
N/A
Long-term Debt
13.9M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T08:36:56.799048 |
Data as of: 2026-03-31 |
Powered by Claude AI